Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Minocycline Pharmacokinetics (ACUMIN)

ClinicalTrials.gov ID: NCT03369951

Public ClinicalTrials.gov record NCT03369951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase IV, multi-center open-label pharmacokinetic trial studying the pharmacokinetics and pharmacodynamics of a single dose of Minocin IV. Up to 67 subjects will be enrolled to obtain 50 evaluable, ICU patients who are already receiving antimicrobial therapy for a known or suspected Gram-negative infection. The entire study duration will be approximately 16 months and each subject participation duration will be approximately 2 days. The study will be conducted at approximately 13 clinical sites. Each subject will receive a single 200 mg dose of Minocin IV infused over approximately 60 minutes. Each subject will have 7 PK samples collected (1 pre-dose, 6 post-dose) at designated time points over a \~48 hour period following the start of the Minocin IV infusion. The primary objectives are: 1) To characterize minocycline PK at the population level in critically-ill adults, with illness known or suspected to be caused by infection with Gram-negative bacteria and 2) To assess patient-level and clinical covariates associated with minocycline pharmacokinetic properties in critically-ill adults, with illness known or suspected to be caused by infection with Gram-negative bacteria.

Study identification

NCT ID
NCT03369951
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
58 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 27, 2018
Primary completion
Jul 19, 2019
Completion
Jul 19, 2019
Last update posted
Dec 2, 2020

2018 – 2019

United States locations

U.S. sites
15
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Emory Decatur Hospital - Clinical Trials - Immunology/Infectious Disease Decatur Georgia 30033
Northwestern Memorial Hospital - ICU Chicago Illinois 60611-2908
Northwestern Medicine - Department of Obstetrics and Gynecology - Division of Female Pelvic Medicine and Reconstructive Surgery Chicago Illinois 60611
University of Kentucky - UK Albert B Chandler Hospital Lexington Kentucky 40536
University of Louisville School of Medicine - Surgery Louisville Kentucky 40202-1622
Henry Ford Health System - Henry Ford Hospital Detroit Michigan 48202-2608
William Beaumont Hospital - Royal Oak Campus - Infectious Disease Royal Oak Michigan 48073-6700
Washington University School of Medicine in St. Louis - Infectious Diseases St Louis Missouri 63110-1010
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit Durham North Carolina 27701
Duke University Hospital - Duke Medicine Pavilion - MICU Durham North Carolina 27710
East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic Greenville North Carolina 27834-9997
University of Cincinnati College of Medicine - Division of Infectious Diseases Cincinnati Ohio 45267
Case Western Reserve University School of Medicine - Medicine - Infectious Diseases and HIV Medicine Cleveland Ohio 44106-1716
Oregon Health and Science University - Division of Pulmonary and Critical Care Medicine Portland Oregon 97239
University of Pittsburgh - Medicine - Infectious Diseases Pittsburgh Pennsylvania 15213-3403

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03369951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 2, 2020 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03369951 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →